Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152508 | 0.88 | P2RX4 (0.39) | P2RX4MAPTSMN1; SMN2NPSR1CDK8 | |
| SCHEMBL1102475 | 0.79 | P2RX4 (0.39) | P2RX4MAPTSMN1; SMN2NPSR1P2RX1 | |
| SCHEMBL1573992 | 0.78 | P2RX4 (0.47) | P2RX4NPSR1P2RX1 | |
| SCHEMBL29379993 | 0.78 | P2RX4 (0.47) | P2RX4NPSR1P2RX1 | |
| SCHEMBL29406608 | 0.78 | P2RX4 (0.47) | P2RX4NPSR1P2RX1 | |
| SCHEMBL13203012 | 0.77 | P2RX4 (0.43) | P2RX4MAPTSMN1; SMN2NPSR1CDK8 | |
| SCHEMBL15458030 | 0.77 | MIF (0.36) | SMN1; SMN2NPSR1 | |
| SCHEMBL13706095 | 0.77 | MGLL (0.46) | P2RX4P2RX1 | |
| SCHEMBL6123852 | 0.77 | P2RX4 (0.39) | P2RX4MAPTSMN1; SMN2NPSR1CDK8 | |
| SCHEMBL10331695 | 0.77 | P2RX4 (0.39) | P2RX4MAPTSMN1; SMN2NPSR1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY2, NR2E3, CRY1 | P2RX4 1277/4885MAPT 530/4885SMN1; SMN2 3217/4885 |
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | CRY2, NR2E3, CRY1 | P2RX4 1277/4885MAPT 530/4885SMN1; SMN2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.